Metraipolis › archive › dc_8a409878ff63

Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients — Europe PMC PMID:40796347

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40796347
DOI
10.1093/jnci/djaf198
License (as archived)
solo-consultazione
Archived
2026-11-08T21:07:10.935Z
SHA-256 of the archived text
ced73821e43af9a1e230a9960f93e57474eb80e90a1d4f86f3bc0cdbd6a48167
Stable URL of this page
https://metraipolis.com/documento/dc_8a409878ff63

How to cite

Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients — Europe PMC PMID:40796347 — Europe PMC (en), https://europepmc.org/article/MED/40796347 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8a409878ff63 (Metraipolis archive dc_8a409878ff63, sha256 ced73821e43af9a1e230a9960f93e57474eb80e90a1d4f86f3bc0cdbd6a48167)
BibTeX
@misc{dc8a409878ff63,
  title = {Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients — Europe PMC PMID:40796347},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40796347},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8a409878ff63; sha256 ced73821e43af9a1e230a9960f93e57474eb80e90a1d4f86f3bc0cdbd6a48167},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40796347. Agents can read the archived copy with the MCP tool read_document.